Back to Insights

How will the change to a more narrow FDA label for Aduhelm (aducanumab) help Biogen?

Posted by Blue Matter on July 14th, 2021.

Varun Renjen, M.D. describes how the recent decision to restrict Aduhelm’s label to earlier-stage patients with mild cognitive impairment (MCI) could be a good thing for Biogen’s new Alzheimer’s therapy. He also outlines three lessons for other pharma companies entering the Alzheimer’s market.

Link here